Abstract CT103: Final results for OptimalTTF-1: Optimizing Tumor Treating Fields with targeted skull remodeling surgery for first recurrence glioblastoma: Phase 1 trial: In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA):

Nikola Mikic; Anders Rosendal Korshoej; Slávka Lukacova; Jens Christian Hedemann Sørensen; Frederik Lundgaard Hansen; Axel Thielscher; Søren Cortnum; Trine Lignell Guldberg; Yasmin Alexandra Lassen; Christian Rahbek; Kåre Severinsen; Gorm von Oettingen

doi:10.1158/1538-7445.AM2020-CT103

Abstract CT103: Final results for OptimalTTF-1: Optimizing Tumor Treating Fields with targeted skull remodeling surgery for first recurrence glioblastoma: Phase 1 trial: In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA):

Nikola Mikic, Anders Rosendal Korshoej, Slávka Lukacova, Jens Christian Hedemann Sørensen, Frederik Lundgaard Hansen, Axel Thielscher, Søren Cortnum, Trine Lignell Guldberg, Yasmin Alexandra Lassen, Christian Rahbek, Kåre Severinsen, Gorm von Oettingen

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Conference abstract in journal › Research › peer-review

Abstract

We present a clinical open label, phase-1 trial (OptimalTTF-1, NCT02893137), which aims to test a novel treatment for first recurrence glioblastoma (rGBM). The aim of the treatment is to optimize the electric field generated by Tumor Treating Fields (TTFields) with targeted and individualized skull-remodeling surgery (SR-surgery). Selectively placed burrholes reduces the electric resistance created by the bone and thus improves the electric field focally. Preclinical research has indicated this conclusion. The final analysis examined the toxicity and efficacy of this combined intervention in addition to best practice chemotherapy.

Original language	English
Article number	CT103
Journal	Cancer Research
Volume	80
Issue	16, suppl.
ISSN	0008-5472
DOIs	https://doi.org/10.1158/1538-7445.AM2020-CT103
Publication status	Published - 2020
Event	AACR Annual Meeting 2020 - Philadelphia, United States Duration: 27 Apr 2020 → 28 Apr 2020

Conference

Conference	AACR Annual Meeting 2020
Country/Territory	United States
City	Philadelphia
Period	27/04/2020 → 28/04/2020

Access to Document

10.1158/1538-7445.AM2020-CT103

Cite this

Mikic, N., Korshoej, A. R., Lukacova, S., Sørensen, J. C. H., Lundgaard Hansen, F., Thielscher, A., Cortnum, S., Guldberg, T. L., Lassen, Y. A., Rahbek, C., Severinsen, K., & Oettingen, G. V. (2020). Abstract CT103: Final results for OptimalTTF-1: Optimizing Tumor Treating Fields with targeted skull remodeling surgery for first recurrence glioblastoma: Phase 1 trial: In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): . Cancer Research, 80(16, suppl.), Article CT103. https://doi.org/10.1158/1538-7445.AM2020-CT103

Mikic, Nikola ; Korshoej, Anders Rosendal ; Lukacova, Slávka et al. / Abstract CT103: Final results for OptimalTTF-1: Optimizing Tumor Treating Fields with targeted skull remodeling surgery for first recurrence glioblastoma: Phase 1 trial : In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): . In: Cancer Research. 2020 ; Vol. 80, No. 16, suppl.

@article{1d935bc9b46645499b5ca8d8754497f1,

title = "Abstract CT103: Final results for OptimalTTF-1: Optimizing Tumor Treating Fields with targeted skull remodeling surgery for first recurrence glioblastoma: Phase 1 trial: In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): ",

abstract = "We present a clinical open label, phase-1 trial (OptimalTTF-1, NCT02893137), which aims to test a novel treatment for first recurrence glioblastoma (rGBM). The aim of the treatment is to optimize the electric field generated by Tumor Treating Fields (TTFields) with targeted and individualized skull-remodeling surgery (SR-surgery). Selectively placed burrholes reduces the electric resistance created by the bone and thus improves the electric field focally. Preclinical research has indicated this conclusion. The final analysis examined the toxicity and efficacy of this combined intervention in addition to best practice chemotherapy.",

author = "Nikola Mikic and Korshoej, {Anders Rosendal} and Sl{\'a}vka Lukacova and S{\o}rensen, {Jens Christian Hedemann} and {Lundgaard Hansen}, Frederik and Axel Thielscher and S{\o}ren Cortnum and Guldberg, {Trine Lignell} and Lassen, {Yasmin Alexandra} and Christian Rahbek and K{\aa}re Severinsen and Oettingen, {Gorm von}",

year = "2020",

doi = "10.1158/1538-7445.AM2020-CT103",

language = "English",

volume = "80",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research (AACR)",

number = "16, suppl.",

note = "AACR Annual Meeting 2020 ; Conference date: 27-04-2020 Through 28-04-2020",

}

Mikic, N , Korshoej, AR , Lukacova, S , Sørensen, JCH, Lundgaard Hansen, F, Thielscher, A, Cortnum, S, Guldberg, TL, Lassen, YA , Rahbek, C , Severinsen, K & Oettingen, GV 2020, 'Abstract CT103: Final results for OptimalTTF-1: Optimizing Tumor Treating Fields with targeted skull remodeling surgery for first recurrence glioblastoma: Phase 1 trial: In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): ', Cancer Research, vol. 80, no. 16, suppl., CT103. https://doi.org/10.1158/1538-7445.AM2020-CT103

Abstract CT103: Final results for OptimalTTF-1: Optimizing Tumor Treating Fields with targeted skull remodeling surgery for first recurrence glioblastoma: Phase 1 trial: In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): . / Mikic, Nikola ; Korshoej, Anders Rosendal ; Lukacova, Slávka et al.
In: Cancer Research, Vol. 80, No. 16, suppl., CT103, 2020.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Conference abstract in journal › Research › peer-review

TY - ABST

T1 - Abstract CT103: Final results for OptimalTTF-1: Optimizing Tumor Treating Fields with targeted skull remodeling surgery for first recurrence glioblastoma: Phase 1 trial

T2 - AACR Annual Meeting 2020

AU - Mikic, Nikola

AU - Korshoej, Anders Rosendal

AU - Lukacova, Slávka

AU - Sørensen, Jens Christian Hedemann

AU - Lundgaard Hansen, Frederik

AU - Thielscher, Axel

AU - Cortnum, Søren

AU - Guldberg, Trine Lignell

AU - Lassen, Yasmin Alexandra

AU - Rahbek, Christian

AU - Severinsen, Kåre

AU - Oettingen, Gorm von

PY - 2020

Y1 - 2020

N2 - We present a clinical open label, phase-1 trial (OptimalTTF-1, NCT02893137), which aims to test a novel treatment for first recurrence glioblastoma (rGBM). The aim of the treatment is to optimize the electric field generated by Tumor Treating Fields (TTFields) with targeted and individualized skull-remodeling surgery (SR-surgery). Selectively placed burrholes reduces the electric resistance created by the bone and thus improves the electric field focally. Preclinical research has indicated this conclusion. The final analysis examined the toxicity and efficacy of this combined intervention in addition to best practice chemotherapy.

AB - We present a clinical open label, phase-1 trial (OptimalTTF-1, NCT02893137), which aims to test a novel treatment for first recurrence glioblastoma (rGBM). The aim of the treatment is to optimize the electric field generated by Tumor Treating Fields (TTFields) with targeted and individualized skull-remodeling surgery (SR-surgery). Selectively placed burrholes reduces the electric resistance created by the bone and thus improves the electric field focally. Preclinical research has indicated this conclusion. The final analysis examined the toxicity and efficacy of this combined intervention in addition to best practice chemotherapy.

U2 - 10.1158/1538-7445.AM2020-CT103

DO - 10.1158/1538-7445.AM2020-CT103

M3 - Conference abstract in journal

SN - 0008-5472

VL - 80

JO - Cancer Research

JF - Cancer Research

IS - 16, suppl.

M1 - CT103

Y2 - 27 April 2020 through 28 April 2020

ER -

Mikic N , Korshoej AR , Lukacova S , Sørensen JCH, Lundgaard Hansen F, Thielscher A et al. Abstract CT103: Final results for OptimalTTF-1: Optimizing Tumor Treating Fields with targeted skull remodeling surgery for first recurrence glioblastoma: Phase 1 trial: In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): . Cancer Research. 2020;80(16, suppl.):CT103. doi: 10.1158/1538-7445.AM2020-CT103